Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Thursday 19 April, Oxford University will play host to an AIMday focused on Biomedical Imaging, which is at the heart of much of the clinical and biomedical research conducted at the University.

Following successful AIMdays focusing on Microscopy and Ageing, in April the Divisional Business Development Team will be running an AIMday in Biomedical Imaging, a broad topic which offers the opportunity to discuss the analysis, enhancement and display of images captured via x-ray, ultrasound, MRI, nuclear medicine and optical imaging technologies. A range of companies including GSK, GE Healthcare, Siemens, and Blue Earth Diagnostics are registered to attend, and it is a fantastic chance for researchers looking to network with industry and discuss relevant questions.

AIMdays are a concept which offer a unique way to facilitate interaction between industry and academia. Born at the University of Uppsala in 2008, they have increasingly gathered attention and use at universities across the globe looking to match researchers with industrial partners.

Interested industry partners are invited to submit questions around a certain topic. At the Microscopy AIMday run in Oxford last year, companies including Zeiss, Olympus, and Andor Technology submitted questions around imaging technologies to aid medical diagnostics, use of virtual reality to understand biological processes, and novel techniques for the future of microscopy research.

Academics then choose which of these questions they would like to answer, depending on their particular area of expertise. The AIMday algorithm designs a programme of one-hour sessions that matches industry partners and academics by their shared interests so that sessions can run in parallel, and interaction between industry and academics is maximised. 

Martin Kerr, Business Development Manager and organiser of the AIMday commented: 'AIMdays are a fantastic opportunity for researchers to spark new collaborations, build their networks, and get a fresh perspective on how their work could be translatable. It also offers early stage researchers exposure to the career paths offered by industry.' 

AIMday Biomedical Imaging takes place on Thu 19 April.  Academic registration opens on Mon 26 Feb – find out more and register.

If you would like to find out more about running an AIMday, please contact Martin Kerr

Similar stories

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology

The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.

Oxford University retains top spot for spinout generation in the UK

Oxford University has been ranked first in the UK for turning academic research into spinout companies, according to a new report published today by data analyst firm Beauhurst.

The glass half full man: Professor Chas Bountra and Oxford's innovative future

Forget the TV clichés about Oxford – all punting and pass the port. The 925-year-old university is full of the most amazing people who are helping and benefiting the world, well beyond the quads and spires, says Professor Chas Bountra, the university’s Pro-Vice-Chancellor for Innovation. After the events of the last two years - and the COVID-19 vaccine [2.5 billion doses delivered and counting] - this most enthusiastic champion of Oxford maintains there can be no doubt, innovation is part and parcel of the historic university’s future. Who knows what is coming next, he says, expectantly.

Exscientia and University of Oxford launch “Xcellomics” program to expedite early-stage academic research and translate novel biology into future drug discovery

Exscientia and the University of Oxford's Target Discovery Institute (TDI) today announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.